Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

GF35L Anti-BDNF Mouse mAb (35928.11)

Anti-BDNF, mouse monoclonal, clone 35928.11, recognizes the ~20 kDa BDNF protein in brain extracts. It is validated for ELISA, Western blotting, immunohistochemistry, and neutralization studies.

Anti-BDNF Mouse mAb (35928.11) MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: Anti-Brain Derived Neurotrophic Factor

GF35L
Purchase on Sigma-Aldrich

Přehled

Replacement Information

Tabulka spec. kláve

Species ReactivityHostAntibody Type
HMMonoclonal Antibody

Products

Katalogové čísloBalení ks/bal.
GF35L-100UG Plastová ampulka 100 μg
Description
OverviewRecognizes the ~20 kDa BDNF protein in brain extracts. Clone 35928.11 was selected based on its ability to neutralize the biological activity of human recombinant BDNF.
Catalogue NumberGF35L
Brand Family Calbiochem®
SynonymsAnti-Brain Derived Neurotrophic Factor
References
ReferencesRiccio, A., et al. 1997. Science 277 1097.
Sendtner, M., et al. 1996. Neurochem. Res. 21, 831.
Barbacid, M. 1995. Ann. N.Y. Acad. Sci. 766, 442.
Gotz, R., et al. 1994. Nature 372, 266.
Snider, W.D. 1994. Cell 77, 627.
Snider, W.D., et al. 1992. J. Neurobiol. 23, 1231.
Product Information
FormLyophilized
FormulationLyophilized from PBS, 5% trehalose.
PreservativeNone
Quality LevelMQ100
Applications
Key Applications Enzyme-Linked Immunosorbent Assay
Immunoblotting (Western Blotting)
Immunohistochemistry
Neutralization Studies
Application NotesELISA (0.5-1 µg/ml)
Immunoblotting (1-2 µg/ml)
Immunohistochemistry (5-15 µg/ml)
Neutralization Studies (see comments)
Application CommentsThe full-length sequence for BDNF can be found under accession number NP_001700. This antibody has been selected for its ability to neutralize the biological activity of human recombinant BDNF. The exact concentration of antibody required to neutralize human recombinant BDNF activity is dependent on the cytokine concentration, cell type, growth conditions, and the type of activity studied. Suggested neutralization concentration required to yield one-half maximal inhibition of BDNF activity is approximately 5-15 µg/ml in the presence of 2.5 ng/ml of human recombinant BDNF, in a neuron survival assay using embryonic chick dorsal root ganglia neurons. The detection limit for human recombinant BDNF is ~300 ng/lane under non-reducing and reducing conditions. The detection for human recombinant BDNF is ~12.5 ng/ml. Based on immunoblotting and ELISA, this antibody exhibits less than 2% cross-reactivity with human recombinant β-NGF, human recombinant NT-3, and human recombinant NT-4. Antibody should be titrated for optimal results in individual systems.
Biological Information
Immunogenrecombinant protein consisting of amino acids 129-247 of human BDNF
ImmunogenHuman
Clone35928.11
HostMouse
IsotypeIgG₁
Species Reactivity
  • Human
Antibody TypeMonoclonal Antibody
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage -20°C
Avoid freeze/thaw Avoid freeze/thaw
Do not freeze Ok to freeze
Special InstructionsWe recommend resuspending the lyophilized antibody with sterile PBS, pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of 100 µg/ml. Following reconstitution, aliquot and freeze (-20°C).
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Katalogové číslo GTIN
GF35L-100UG 04055977220124

Documentation

Anti-BDNF Mouse mAb (35928.11) MSDS

Title

Safety Data Sheet (SDS) 

Anti-BDNF Mouse mAb (35928.11) Certificates of Analysis

TitleLot Number
GF35L

References

Přehled odkazů
Riccio, A., et al. 1997. Science 277 1097.
Sendtner, M., et al. 1996. Neurochem. Res. 21, 831.
Barbacid, M. 1995. Ann. N.Y. Acad. Sci. 766, 442.
Gotz, R., et al. 1994. Nature 372, 266.
Snider, W.D. 1994. Cell 77, 627.
Snider, W.D., et al. 1992. J. Neurobiol. 23, 1231.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision12-April-2010 JSW
SynonymsAnti-Brain Derived Neurotrophic Factor
ApplicationELISA (0.5-1 µg/ml)
Immunoblotting (1-2 µg/ml)
Immunohistochemistry (5-15 µg/ml)
Neutralization Studies (see comments)
DescriptionImmunoaffinty purified mouse monoclonal antibody. Recognizes the ~20 kDa BDNF protein.
BackgroundNeurotrophic factors define a family of related proteins, which are important in the development, maintenance, and regulation of neurons in both the peripheral and central nervous system. In addition to the prototypical nerve growth factor (NGF), several other factors have been identified which interact with a family of tyrosine kinase receptors. TrkA is the kinase signaling receptor for NGF, while TrkB mediates signaling for both brain-derived neurotrophic factor (BDNF) and neurotrophin-4/5 (NT-4/5). TrkC is the primary receptor for neurotrophin-3 (NT-3), although this neurotrophin can also activate TrkA and TrkB receptors under certain conditions. Axotomy-induced cell death is one experimental paradigm that has been used to discriminate between the effects of various neurotrophic factors on the survival of different neuronal populations. BDNF, NT-3, and NT-4/5 act as motor neuron survival factors, whereas NGF has no effect on the survival of spinal cord motor neurons. NGF is neuroprotective for cholinergic neurons in the central nervous system. Retrogradely transported NGF-TrkA has also been shown to signal the CREB transcription factor in sympathetic neurons. A putative new member of this gene family, neurotrophin-6 (NT-6), has also been identified from the fish Xephophorus. Like NGF, NT-6 promotes the survival of sympathetic and sensory neurons, albeit with a lower potency.
HostMouse
Immunogen speciesHuman
Immunogenrecombinant protein consisting of amino acids 129-247 of human BDNF
Clone35928.11
IsotypeIgG₁
Specieshuman
FormLyophilized
FormulationLyophilized from PBS, 5% trehalose.
PreservativeNone
CommentsThe full-length sequence for BDNF can be found under accession number NP_001700. This antibody has been selected for its ability to neutralize the biological activity of human recombinant BDNF. The exact concentration of antibody required to neutralize human recombinant BDNF activity is dependent on the cytokine concentration, cell type, growth conditions, and the type of activity studied. Suggested neutralization concentration required to yield one-half maximal inhibition of BDNF activity is approximately 5-15 µg/ml in the presence of 2.5 ng/ml of human recombinant BDNF, in a neuron survival assay using embryonic chick dorsal root ganglia neurons. The detection limit for human recombinant BDNF is ~300 ng/lane under non-reducing and reducing conditions. The detection for human recombinant BDNF is ~12.5 ng/ml. Based on immunoblotting and ELISA, this antibody exhibits less than 2% cross-reactivity with human recombinant β-NGF, human recombinant NT-3, and human recombinant NT-4. Antibody should be titrated for optimal results in individual systems.
Storage Avoid freeze/thaw
-20°C
Do Not Freeze Ok to freeze
Special InstructionsWe recommend resuspending the lyophilized antibody with sterile PBS, pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of 100 µg/ml. Following reconstitution, aliquot and freeze (-20°C).
Toxicity Standard Handling
ReferencesRiccio, A., et al. 1997. Science 277 1097.
Sendtner, M., et al. 1996. Neurochem. Res. 21, 831.
Barbacid, M. 1995. Ann. N.Y. Acad. Sci. 766, 442.
Gotz, R., et al. 1994. Nature 372, 266.
Snider, W.D. 1994. Cell 77, 627.
Snider, W.D., et al. 1992. J. Neurobiol. 23, 1231.